Department of General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan.
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Medicine (Baltimore). 2021 Nov 24;100(47):e27952. doi: 10.1097/MD.0000000000027952.
Respiratory syncytial virus (RSV) infection is an important cause of hospitalization in infants and young children. Monthly administration of palivizumab during the RSV season is effective in preventing severe infections in children with comorbidities. However, determining the onset of the RSV season for starting palivizumab is often challenging. The present study aimed to evaluate the ideal timing to start palivizumab and its effect on hospitalization in the real world.We performed a retrospective, observational study to identify the relationship between the timing of the first dose of palivizumab administration and RSV-related hospitalization. Medical records from 2015 to 2019 were reviewed. We included patients who had indications for palivizumab as of July 1 in each year. We counted the proportion of children receiving palivizumab and the number of RSV infection-related hospitalizations each month. We also evaluated the differences in background and underlying disease between children with and without hospitalization.A total of 498 patients were included, and 105 (21.0%) completed the first dose in July when the RSV season usually begins in Japan. Twenty-three (4.6%) patients were hospitalized for RSV infection during the observation period, with 13 (56.5%) hospitalizations before their first dose of palivizumab. The remaining 10 patients were hospitalized after receiving 1 or more doses of palivizumab. Children living with siblings and children with cyanosis originating from congenital heart disease had a higher risk of RSV with odds ratios of 5.1 (95% confidence interval 1.48-17.6, P < .01) and 3.3 (95% confidence interval 1.33-7.94, P < .01), respectively.Delays in administering palivizumab at the beginning of the season increases the rate of RSV infection-related hospitalization. To maximize prophylactic effectiveness, administering the first dose as early as possible in the RSV season is crucial, with priority for cyanotic children or those with siblings.
呼吸道合胞病毒(RSV)感染是导致婴儿和幼儿住院的重要原因。在 RSV 季节每月给予帕利珠单抗可有效预防合并症儿童的严重感染。然而,确定 RSV 季节开始使用帕利珠单抗的时间通常具有挑战性。本研究旨在评估开始使用帕利珠单抗的最佳时间及其对现实世界中住院的影响。
我们进行了一项回顾性观察性研究,以确定帕利珠单抗首次给药时间与 RSV 相关住院之间的关系。回顾了 2015 年至 2019 年的病历。我们纳入了当年 7 月 1 日前有使用帕利珠单抗指征的患者。我们按月计算接受帕利珠单抗治疗的儿童比例和 RSV 感染相关住院人数。我们还评估了有和无住院的儿童在背景和基础疾病方面的差异。
共纳入 498 例患者,其中 105 例(21.0%)在日本 RSV 季节通常开始时于 7 月完成了首剂。在观察期间,有 23 例(4.6%)患者因 RSV 感染住院,其中 13 例(56.5%)在接受帕利珠单抗首剂前住院。其余 10 例患者在接受 1 剂或多剂帕利珠单抗后住院。与兄弟姐妹同住的儿童和因先天性心脏病引起发绀的儿童发生 RSV 的风险更高,优势比分别为 5.1(95%置信区间 1.48-17.6,P <.01)和 3.3(95%置信区间 1.33-7.94,P <.01)。
在季节开始时延迟给予帕利珠单抗会增加 RSV 感染相关住院的发生率。为了最大限度地提高预防效果,在 RSV 季节尽早给予首剂至关重要,对于发绀儿童或有兄弟姐妹的儿童应优先考虑。